These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 2301022)

  • 1. Living-donor renal transplantation in SEOPF. The impact of histocompatibility, transfusions, and cyclosporine on outcome.
    Sanfilippo F; Thacker L; Vaughn WK
    Transplantation; 1990 Jan; 49(1):25-9. PubMed ID: 2301022
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term graft survival with or without donor-specific transfusion in cyclosporine era in one haplo-identical living-related renal transplant recipients beyond the first year: a 19-year experience.
    Satoh S; Sugimura J; Omori S; Seino K; Fujizuka I
    Tohoku J Exp Med; 2002 Aug; 197(4):201-7. PubMed ID: 12434995
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Minimal sensitization and excellent renal allograft outcome following donor-specific blood transfusion with a short course of cyclosporine.
    Cheigh JS; Suthanthiran M; Fotino M; Riggio RR; Schechter N; Stubenbord WT; Stenzel KH; Rubin AL
    Transplantation; 1991 Feb; 51(2):378-81. PubMed ID: 1825244
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Donor-specific transfusion: a report of the Japanese Renal Transplant Registry.
    Sonoda T; Ishibashi M
    Clin Transpl; 1987; ():257-60. PubMed ID: 2978999
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of ultraviolet-B-irradiated donor-specific blood transfusions and peritransplant immunosuppression with cyclosporine on rat cardiac allograft survival.
    Oluwole SF; Lau HT; Reemtsma K; Hardy MA
    Transplantation; 1988 Feb; 45(2):293-7. PubMed ID: 3278417
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Donor specific transfusions or cyclosporine for related-donor kidney transplantation?
    Jayes RL; Levey AS
    Kidney Int; 1989 Sep; 36(3):485-96. PubMed ID: 2593493
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Are blood transfusions beneficial in the cyclosporine era?
    Potter DE; Portale AA; Melzer JS; Feduska NJ; Garovoy MR; Husing RM; Salvatierra O
    Pediatr Nephrol; 1991 Jan; 5(1):168-72. PubMed ID: 2025530
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Extensive prolongation of rat renal allograft survival following donor or nonspecific transfusions and concomitant immunosuppressant.
    Martin DC; Hewitt CW; Black KS; Dowdy SF; Quintero CS; Reyes M
    Transplantation; 1987 Jun; 43(6):790-4. PubMed ID: 3296345
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Factors influencing cadaver kidney transplantation outcome in the cyclosporine era. The North Italy Transplant Program (NITp).
    Clin Transpl; 1988; ():131-45. PubMed ID: 3154466
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Conventional immunosuppression after deliberate third party transfusions versus cyclosporine in living related renal transplant recipients.
    Hodge EE; Banowsky LH; Novick AC; Lewis RM; Streem SB; Steinmuller DR; Holzmann JJ; McFarlin L; Graneto DE
    J Urol; 1989 Mar; 141(3):495-8. PubMed ID: 2645417
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The transfusion effect.
    Cecka JM
    Clin Transpl; 1987; ():287-301. PubMed ID: 3154420
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of donor-specific blood transfusion, cyclosporine, and dietary prostaglandin precursors on rat cardiac allograft survival. II. Effectiveness of a 24-hour induction period with DST and CsA in inducing long-term graft survival.
    Tchervenkov JI; Epstein MD; Alexander JW; Schroeder TJ
    Transplantation; 1989 Jan; 47(1):177-81. PubMed ID: 2643225
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Donor-specific blood transfusions versus cyclosporine--the DST story.
    Salvatierra O; Melzer J; Vincenti F; Amend WJ; Tomlanovich S; Potter D; Husing R; Garovoy M; Feduska NJ
    Transplant Proc; 1987 Feb; 19(1 Pt 1):160-6. PubMed ID: 3547813
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of a single pretransplant donor-specific transfusion and cyclosporin A administered 24 to 48 hours before one-haplotype-mismatched living related donor kidney transplant.
    Davies CB; Alexander JW; Cofer BR; First MR; Schroeder TJ
    Ann Surg; 1992 Jun; 215(6):618-25; discussion 626. PubMed ID: 1632683
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HLA matching for cadaver renal transplantation in SEOPF: the impact of cyclosporine. Southeastern Organ Procurement Foundation.
    Sanfilippo F; Vaughn WK; Lefor WM
    Clin Transpl; 1986; ():109-20. PubMed ID: 3154372
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhancement of allograft survival by donor-specific transfusion one day prior to transplant. Importance of timing and specificity when DST is given with cyclosporine.
    Brunson ME; Tchervenkov JI; Alexander JW
    Transplantation; 1991 Sep; 52(3):545-9. PubMed ID: 1716800
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prospective randomized study of azathioprine vs cyclosporine based therapy in primary haplo-identical living-donor kidney transplantation: 20-year experience.
    Gheith OA; Bakr MA; Fouda MA; Shokeir AA; Sobh M; Ghoneim M
    Clin Exp Nephrol; 2007 Jun; 11(2):151-155. PubMed ID: 17593515
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multivariate analysis of donor-specific versus random transfusion protocols in haploidentical living-related transplants.
    Reed A; Pirsch J; Armbrust MJ; Burlingham WJ; Knechtle SJ; D'Alessandro AM; Sollinger HW; Lorentzen D; Kalayoglu M; Belzer FO
    Transplantation; 1991 Feb; 51(2):382-4. PubMed ID: 1994532
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evidence that HLA class II disparity is required for the induction of renal allograft enhancement by donor-specific blood transfusions in man.
    Lazda VA; Pollak R; Mozes MF; Barber PL; Jonasson O
    Transplantation; 1990 Jun; 49(6):1084-7. PubMed ID: 2360251
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Donor-specific transfusions have long-term beneficial effects for human renal allografts.
    Flye MW; Burton K; Mohanakumar T; Brennan D; Keller C; Goss JA; Sicard GA; Anderson CB
    Transplantation; 1995 Dec; 60(12):1395-401. PubMed ID: 8545863
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.